| Line 1: |
Line 1: |
| | =Content site= | | =Content site= |
| | | | |
| − | {{DISPLAYTITLE:Follicular dendritic cell sarcoma}}
| + | '''Welcome to the Compendium of Cancer Genome Aberrations (CCGA)! The CCGA is a collaborative effort to document and describe clinically relevant chromosome and other genomic abnormalities in cancer structured based on [https://tumourclassification.iarc.who.int/welcome/ current WHO classification] as published by [https://whobluebooks.iarc.fr/about/ IARC]. The Wiki style interface allows for real-time editing and content sharing within our genetics community. This resource is sponsored and supported by the [http://www.cancergenomics.org <u>Cancer Genomics Consortium (CGC)</u>] and contributed to by colleagues with an interest in clinical cytogenetics, molecular genetics and genomics in cancer.''' |
| − | [[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]] | |
| | | | |
| − | {{Under Construction}}
| + | *Join the CCGA community! If you would like to contribute as an '''<u>[[Description of CCGA Roles|Author or Other Role]]</u>''', please complete a few brief questions on our '''[https://mms.cancergenomics.org/members/form.php?orgcode=CGC&fid=3830649 <u>Volunteer Form</u>]'''. We are creating content for all diseases with genetic findings in the current WHO Classification of Tumours books. [[Volunteer Assignments and Opportunities|'''<u>Please join the effort by looking through the authorship opportunities</u>''']]! |
| | | | |
| − | <blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Follicular Dendritic Cell Sarcoma]].
| + | *'''[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]''' for more information or suggestions for updates. |
| − | }}</blockquote>
| |
| − | ==Primary Author(s)*==
| |
| | | | |
| − | Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
| + | *Meet our '''<u>[[Leadership|Editorial Leadership]]</u>''', '''<u>[[CCGA Workgroup|CCGA Workgroup Members]]</u>''' and [[Communications Liaison|<u>'''Communications Liaison'''</u>]]. |
| | | | |
| − | __TOC__
| + | *For contributors, we've created a '''<u>[[Video_Tutorial|Video Tutorial]]</u>''' demonstrating how to add content to the CCGA. Please also refer to helpful '''<u>[[Author Instructions|Author Instructions]]</u>'''. |
| | + | *Become a part of our Twitter family for the latest updates [https://twitter.com/ccgawiki '''@ccgawiki''']. |
| | + | <inputbox> |
| | + | type=search2 |
| | + | break=no |
| | + | placeholder=enter search term |
| | + | </inputbox> |
| | + | [[File:Generic book cover heme and lymphoid.jpg|thumb|link=HAEM5:Table_of_Contents|Search content structured based on the WHO Classification ('''click book image'''). ''Reference: WHO Classification of Tumours Editorial Board. [https://tumourclassification.iarc.who.int/chapters/63 Haematolymphoid tumours] [Internet; beta version ahead of print]. Lyon (France): International Agency for Research on Cancer; 2022. The hierarchical tumour classification structure is reproduced from the [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours] with permission from the copyright holder, ©International Agency for Research on Cancer.''|alt=]] |
| | | | |
| − | ==Cancer Category / Type==
| |
| | | | |
| − | [[HAEM4:Histiocytic and Dendritic Cell Neoplasms]] (WHO 4th ed.)<ref name=":0">Chan JKC, et al., (2017). Follicular dendritic cell sarcoma, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.</ref> | + | [[File:Inv 16 pathology.png |100px|link=:Category:Diseases]] '''Diseases''' '''[[:Category:Diseases A|A]]''' |
| | + | | '''[[:Category:Diseases B|B]]''' | '''[[:Category:Diseases C|C]]''' | '''[[:Category:Diseases D|D]]''' | '''[[:Category:Diseases E|E]]''' | '''[[:Category:Diseases F|F]]''' |
| | + | | '''[[:Category:Diseases G|G]]''' | '''[[:Category:Diseases H|H]]''' | '''[[:Category:Diseases I|I]]''' | '''[[:Category:Diseases J|J]]''' | '''[[:Category:Diseases K|K]]''' | '''[[:Category:Diseases L|L]]''' | '''[[:Category:Diseases M|M]]''' | '''[[:Category:Diseases N|N]]''' | '''[[:Category:Diseases O|O]]''' | '''[[:Category:Diseases P|P]]''' | '''[[:Category:Diseases Q|Q]]''' | '''[[:Category:Diseases R|R]]''' | '''[[:Category:Diseases S|S]]''' | '''[[:Category:Diseases T|T]]''' | '''[[:Category:Diseases U|U]]''' |
| | + | | '''[[:Category:Diseases V|V]]''' | '''[[:Category:Diseases W|W]]''' | '''[[:Category:Diseases X|X]]''' | '''[[:Category:Diseases Y|Y]]''' | '''[[:Category:Diseases Z|Z]]''' |
| | | | |
| − | Stroma-derived neoplasms of lymphoid tissues (WHO 5th ed.)<ref name=":1">{{Cite journal|last=Alaggio|first=Rita|last2=Amador|first2=Catalina|last3=Anagnostopoulos|first3=Ioannis|last4=Attygalle|first4=Ayoma D.|last5=Araujo|first5=Iguaracyra Barreto de Oliveira|last6=Berti|first6=Emilio|last7=Bhagat|first7=Govind|last8=Borges|first8=Anita Maria|last9=Boyer|first9=Daniel|date=2022-07|title=The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms|url=https://pubmed.ncbi.nlm.nih.gov/35732829|journal=Leukemia|volume=36|issue=7|pages=1720–1748|doi=10.1038/s41375-022-01620-2|issn=1476-5551|pmc=9214472|pmid=35732829}}</ref>
| |
| | | | |
| − | ==Cancer Sub-Classification / Subtype==
| |
| | | | |
| − | Mesenchymal dendritic cell neoplasms (WHO 5th ed.)<ref name=":1" />
| |
| | | | |
| − | ==Definition / Description of Disease== | + | [[File:Fish_zoomed.png|100px|link=:Category:Cancer Genes]] '''Cancer Genes''' '''[[:Category:Cancer Genes A|A]]''' |
| | + | | '''[[:Category:Cancer Genes B|B]]''' | '''[[:Category:Cancer Genes C|C]]''' | '''[[:Category:Cancer Genes D|D]]''' | '''[[:Category:Cancer Genes E|E]]''' | '''[[:Category:Cancer Genes F|F]]''' |
| | + | | '''[[:Category:Cancer Genes G|G]]''' | '''[[:Category:Cancer Genes H|H]]''' | '''[[:Category:Cancer Genes I|I]]''' | '''[[:Category:Cancer Genes J|J]]''' | '''[[:Category:Cancer Genes K|K]]''' | '''[[:Category:Cancer Genes L|L]]''' | '''[[:Category:Cancer Genes M|M]]''' | '''[[:Category:Cancer Genes N|N]]''' | '''[[:Category:Cancer Genes O|O]]''' | '''[[:Category:Cancer Genes P|P]]''' | '''[[:Category:Cancer Genes Q|Q]]''' | '''[[:Category:Cancer Genes R|R]]''' | '''[[:Category:Cancer Genes S|S]]''' | '''[[:Category:Cancer Genes T|T]]''' | '''[[:Category:Cancer Genes U|U]]''' |
| | + | | '''[[:Category:Cancer Genes V|V]]''' | '''[[:Category:Cancer Genes W|W]]''' | '''[[:Category:Cancer Genes X|X]]''' | '''[[:Category:Cancer Genes Y|Y]]''' | '''[[:Category:Cancer Genes Z|Z]]''' |
| | + | <br /><br /> |
| | + | <br> |
| | + | [[File:CGC logo only.png|100px|link=Main_Page]]<span id="fp-span-cgc-pre"> '''CGC Workgroups Recurrent Loci Tables'''</span><span id="fp-span-cgc" style="display: block; margin-top: -62px; margin-left: 385px;"> [[AML Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray|AML]] | [[MDS, MDS/MPN and MPN Tables: Recurrent Genomic Alterations Detected by Chromosomal Microarray|MDS/MPN]] | [[CLL Tables: Regions of Recurrent Copy Number Change and CN-LOH|CLL]] | [[Recurrent Genomic Alterations in Pediatric and Adult Central Nervous System Tumors Detected by Chromosomal Microarray|CNS Tumors]] | [[Plasma Cell Neoplasms Tables: Recurrent Cytogenomic Alterations|Plasma Cell Neoplasms]] | [[Breast Cancer Table: Recurrent Genomic Alterations Detected by Chromosomal Microarray|Breast Cancer]] | [[Renal Cell Neoplasia Tables: Recurrent Cytogenomic Alterations|Renal Neoplasia]] | [[B-ALL Tables: Prognostic Genomic Abnormalities and Recurrent Gene Fusions|B-ALL]]</span> |
| | + | <br> |
| | + | <br> |
| | + | <br> |
| | + | <div style="clear: both;"></div> |
| | + | <div id="bottom-fp-links" style="margin: auto;"> |
| | + | <div style="height:150px;"> |
| | + | <div class="bottom-fp-links-column" style="width: 24%; float: left;"> |
| | + | <div style="float: left; padding-right: 10px; height: 150px;"> |
| | + | [[File:Plus2.png|30px|link=About]] |
| | + | </div> |
| | + | <div> |
| | + | <h4>[[Submit an Article]]</h4> |
| | + | [[Video Tutorial]] |
| | + | |
| | + | [[Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1); RUNX1-RUNX1T1|Example Article]] |
| | + | </div> |
| | + | </div> |
| | + | <div class="bottom-fp-links-column" style="width: 24%; float: left;"> |
| | + | <div style="float: left; padding-right: 10px; height: 150px;"> |
| | + | [[File:Star.png|45px|link=About]] |
| | + | </div> |
| | + | <div> |
| | + | <h4>Resources</h4> |
| | + | [[BED Files]] |
| | | | |
| − | Follicular dendritic cell sarcoma (FDCS) is a neoplasm with morphologic and immunophenotypic features of follicular dendritic cells, which are normally present in lymphoid follicles and are derived from mesenchymal cells of lymphoid tissues.
| + | [[Technical Standards and Protocols]] |
| | | | |
| − | ==Synonyms / Terminology== | + | </div> |
| | + | </div> |
| | + | <div class="bottom-fp-links-column" style="width: 24%; float: left;"> |
| | + | <div style="float: left; padding-left: 10px; padding-right: 20px; height: 150px;"> |
| | + | [[File:Arrow.png|30px|link=About]] |
| | + | </div> |
| | + | <div> |
| | + | <h4>[[Join Us!]]</h4> |
| | + | [[Request Membership]] |
| | | | |
| − | Follicular dendritic cell tumor
| + | </div> |
| | + | </div> |
| | + | <div class="bottom-fp-links-column" style="width: 24%; float: left;"> |
| | + | <div style="float: left; padding-left: 10px; padding-right: 20px; height: 150px;"> |
| | + | [[File:Ask.png|30px|link=About]] |
| | + | </div> |
| | + | <div> |
| | + | <h4>FAQ</h4> |
| | + | [[Frequently Asked Questions (FAQs)|Frequently Asked Questions]] |
| | | | |
| − | Dendritic reticulum cell tumor (no longer used)
| + | </div> |
| | + | </div> |
| | + | </div> |
| | + | |
| | + | </div> |
| | | | |
| − | ==Epidemiology / Prevalence==
| |
| | | | |
| − | Put your text here
| + | {{Template:Disclaimer}} |
| | | | |
| − | ==Clinical Features==
| + | __NOTOC__ |
| − | | + | __NOEDITSECTION__ |
| − | Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>
| |
| − | {| class="wikitable"
| |
| − | |'''Signs and Symptoms'''
| |
| − | |EXAMPLE Asymptomatic (incidental finding on complete blood counts)
| |
| − | | |
| − | EXAMPLE B-symptoms (weight loss, fever, night sweats)
| |
| − | | |
| − | EXAMPLE Fatigue
| |
| − | | |
| − | EXAMPLE Lymphadenopathy (uncommon)
| |
| − | |-
| |
| − | |'''Laboratory Findings'''
| |
| − | |EXAMPLE Cytopenias
| |
| − | | |
| − | EXAMPLE Lymphocytosis (low level)
| |
| − | |}
| |
| − | | |
| − | ==Sites of Involvement==
| |
| − | | |
| − | *Extranodal sites (79%)
| |
| − | **Liver, spleen, and GI tract most common
| |
| − | **Any site may be involved
| |
| − | *Lymph nodes (~15%)<ref name=":2">{{Cite journal|last=Facchetti|first=Fabio|last2=Simbeni|first2=Matteo|last3=Lorenzi|first3=Luisa|date=2021-10|title=Follicular dendritic cell sarcoma|url=https://pubmed.ncbi.nlm.nih.gov/34837090|journal=Pathologica|volume=113|issue=5|pages=316–329|doi=10.32074/1591-951X-331|issn=1591-951X|pmc=8720404|pmid=34837090}}</ref>
| |
| − | | |
| − | ==Morphologic Features==
| |
| − | | |
| − | Put your text here
| |
| − | | |
| − | ==Immunophenotype==
| |
| − | | |
| − | | |
| − | {| class="wikitable sortable"
| |
| − | |-
| |
| − | !Finding!!Marker
| |
| − | |-
| |
| − | |Positive (lineage-defining)||One or more of CD21, CD23, CD35
| |
| − | |-
| |
| − | |Positive (frequent)||CXCL13, clusterin, podoplanin, fascin, vimentin
| |
| − | |-
| |
| − | |Positive (variable)
| |
| − | |CD68, EMA, S100
| |
| − | |-
| |
| − | |Negative (universal)||CD1a, langerin, CD34, CD45, lysozyme, CD163, MPO, CD3, CD79a, cytokeratins, HMB-45
| |
| − | |}
| |
| − | | |
| − | | |
| − | <blockquote class='blockedit'>{{Box-round|title=Unassigned References|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref name=":0" /><ref name=":2" /></blockquote>
| |
| − | ==Chromosomal Rearrangements (Gene Fusions)==
| |
| − | | |
| − | Put your text here and fill in the table
| |
| − | | |
| − | {| class="wikitable sortable"
| |
| − | |-
| |
| − | !Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence
| |
| − | !Diagnostic Significance (Yes, No or Unknown)
| |
| − | !Prognostic Significance (Yes, No or Unknown)
| |
| − | !Therapeutic Significance (Yes, No or Unknown)
| |
| − | !Notes
| |
| − | |-
| |
| − | |EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 20% (COSMIC)
| |
| − | EXAMPLE 30% (add reference)
| |
| − | |Yes
| |
| − | |No
| |
| − | |Yes
| |
| − | |EXAMPLE
| |
| − | | |
| − | The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).
| |
| − | |}
| |
| − |
| |
| − | | |
| − | <blockquote class='blockedit'>{{Box-round|title=v4:Chromosomal Rearrangements (Gene Fusions)|The content below was from the old template. Please incorporate above.}}
| |
| − | | |
| − | The following rearrangements have been reported in individual cases, but whether they are recurrent is not yet known.
| |
| − | | |
| − | {| class="wikitable sortable"
| |
| − | |-
| |
| − | !Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence
| |
| − | |-
| |
| − | |EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 5%
| |
| − | |-
| |
| − | |EXAMPLE t(8;21)(q22;q22)||EXAMPLE 5'RUNX1 / 3'RUNXT1||EXAMPLE der(8)||EXAMPLE 5%
| |
| − | |}
| |
| − |
| |
| − | </blockquote>
| |
| − | ==Individual Region Genomic Gain / Loss / LOH==
| |
| − | | |
| − | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
| |
| − | | |
| − | {| class="wikitable sortable"
| |
| − | |-
| |
| − | !Chr #!!Gain / Loss / Amp / LOH!!Minimal Region Genomic Coordinates [Genome Build]!!Minimal Region Cytoband
| |
| − | !Diagnostic Significance (Yes, No or Unknown)
| |
| − | !Prognostic Significance (Yes, No or Unknown)
| |
| − | !Therapeutic Significance (Yes, No or Unknown)
| |
| − | !Notes
| |
| − | |-
| |
| − | |EXAMPLE
| |
| − | | |
| − | 7
| |
| − | |EXAMPLE Loss
| |
| − | |EXAMPLE
| |
| − | | |
| − | chr7:1- 159,335,973 [hg38]
| |
| − | |EXAMPLE
| |
| − | | |
| − | chr7
| |
| − | |Yes
| |
| − | |Yes
| |
| − | |No
| |
| − | |EXAMPLE
| |
| − | | |
| − | Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).
| |
| − | |-
| |
| − | |EXAMPLE
| |
| − | | |
| − | 8
| |
| − | |EXAMPLE Gain
| |
| − | |EXAMPLE
| |
| − | | |
| − | chr8:1-145,138,636 [hg38]
| |
| − | |EXAMPLE
| |
| − | | |
| − | chr8
| |
| − | |No
| |
| − | |No
| |
| − | |No
| |
| − | |EXAMPLE
| |
| − | | |
| − | Common recurrent secondary finding for t(8;21) (add reference).
| |
| − | |}
| |
| − | ==Characteristic Chromosomal Patterns==
| |
| − | | |
| − | Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis'')</span>
| |
| − | | |
| − | {| class="wikitable sortable"
| |
| − | |-
| |
| − | !Chromosomal Pattern
| |
| − | !Diagnostic Significance (Yes, No or Unknown)
| |
| − | !Prognostic Significance (Yes, No or Unknown)
| |
| − | !Therapeutic Significance (Yes, No or Unknown)
| |
| − | !Notes
| |
| − | |-
| |
| − | |EXAMPLE
| |
| − | | |
| − | Co-deletion of 1p and 18q
| |
| − | |Yes
| |
| − | |No
| |
| − | |No
| |
| − | |EXAMPLE:
| |
| − | | |
| − | See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
| |
| − | |}
| |
| − | | |
| − | <blockquote class='blockedit'>{{Box-round|title=v4:Characteristic Chromosomal Aberrations / Patterns|The content below was from the old template. Please incorporate above.}}
| |
| − | | |
| − | Although no recurrent chromosomal alterations have been identified in FDCS, the tumors often show complex karyotypes with loss of whole or partial chromosomes being the most frequent aberration. Losses frequently occur in regions harboring important tumor suppressor genes.<ref name=":2" />
| |
| − | | |
| − | </blockquote>
| |
| − | ==Gene Mutations (SNV / INDEL)==
| |
| − | | |
| − | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
| |
| − | | |
| − | {| class="wikitable sortable"
| |
| − | |-
| |
| − | !Gene; Genetic Alteration!!'''Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)'''!!'''Prevalence (COSMIC / TCGA / Other)'''!!'''Concomitant Mutations'''!!'''Mutually Exclusive Mutations'''
| |
| − | !'''Diagnostic Significance (Yes, No or Unknown)'''
| |
| − | !Prognostic Significance (Yes, No or Unknown)
| |
| − | !Therapeutic Significance (Yes, No or Unknown)
| |
| − | !Notes
| |
| − | |-
| |
| − | |EXAMPLE: TP53; Variable LOF mutations
| |
| − | | |
| − | EXAMPLE:
| |
| − | | |
| − | EGFR; Exon 20 mutations
| |
| − | | |
| − | EXAMPLE: BRAF; Activating mutations
| |
| − | |EXAMPLE: TSG
| |
| − | |EXAMPLE: 20% (COSMIC)
| |
| − | | |
| − | EXAMPLE: 30% (add Reference)
| |
| − | |EXAMPLE: IDH1 R123H
| |
| − | |EXAMPLE: EGFR amplification
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |EXAMPLE: Excludes hairy cell leukemia (HCL) (add reference).
| |
| − | <br />
| |
| − | |}
| |
| − | Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
| |
| − | | |
| − | | |
| − | <blockquote class='blockedit'>{{Box-round|title=v4:Gene Mutations (SNV/INDEL)|The content below was from the old template. Please incorporate above.}}
| |
| − | | |
| − | Put your text here and/or fill in the tables
| |
| − | | |
| − | {| class="wikitable sortable"
| |
| − | |-
| |
| − | !Gene!!Mutation!!Oncogene/Tumor Suppressor/Other!!Presumed Mechanism (LOF/GOF/Other; Driver/Passenger)!!Prevalence (COSMIC/TCGA/Other)
| |
| − | |-
| |
| − | |''CDKN2A''||Copy number loss||Tumor Suppressor|| ||
| |
| − | |-
| |
| − | |''NFKBIA''
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''TP53''
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''BIRC3''
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''CCND2''
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''BRAF''
| |
| − | |p.V600E
| |
| − | |
| |
| − | |
| |
| − | |0-19%
| |
| − | |-
| |
| − | |''TRAF3''
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''TNFAIP3''
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''RB1''
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''CDK4/MDM2''
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''PTEN''
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''JAK2''
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''SOCS3''
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''BRCA1/BRCA2''
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''KRAS''
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |''MYC''
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |-
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |
| |
| − | |}
| |
| − |
| |
| − | ===Other Mutations===
| |
| − | {| class="wikitable sortable"
| |
| − | |-
| |
| − | !Type!!Gene/Region/Other
| |
| − | |-
| |
| − | |Concomitant Mutations||EXAMPLE IDH1 R123H
| |
| − | |-
| |
| − | |Secondary Mutations||EXAMPLE Trisomy 7
| |
| − | |-
| |
| − | |Mutually Exclusive||EXAMPLE EGFR Amplification
| |
| − | |}
| |
| − | | |
| − | </blockquote>
| |
| − | ==Epigenomic Alterations==
| |
| − | | |
| − | Put your text here
| |
| − | | |
| − | ==Genes and Main Pathways Involved==
| |
| − | | |
| − | Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table.'')</span>
| |
| − | {| class="wikitable sortable"
| |
| − | |-
| |
| − | !Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
| |
| − | |-
| |
| − | |EXAMPLE: BRAF and MAP2K1; Activating mutations
| |
| − | |EXAMPLE: MAPK signaling
| |
| − | |EXAMPLE: Increased cell growth and proliferation
| |
| − | |-
| |
| − | |EXAMPLE: CDKN2A; Inactivating mutations
| |
| − | |EXAMPLE: Cell cycle regulation
| |
| − | |EXAMPLE: Unregulated cell division
| |
| − | |-
| |
| − | |EXAMPLE: KMT2C and ARID1A; Inactivating mutations
| |
| − | |EXAMPLE: Histone modification, chromatin remodeling
| |
| − | |EXAMPLE: Abnormal gene expression program
| |
| − | |}
| |
| − | | |
| − | <blockquote class='blockedit'>{{Box-round|title=v4:Genes and Main Pathways Involved|The content below was from the old template. Please incorporate above.}}
| |
| − | | |
| − | FDCS primarily shows alterations in the NF-κB signaling pathway. Unlike the dendritic cell and histiocytic neoplasms of hematopoietic origin, aberrations in the MAPK pathway are uncommon.
| |
| − | | |
| − | </blockquote>
| |
| − | ==Genetic Diagnostic Testing Methods==
| |
| − | | |
| − | The only current method of diagnosis is tissue biopsy with immunohistochemistry. FDCS must be differentiated from other mesenchymal dendritic cell neoplasms, histiocytic and dendritic cell neoplasms, and non-hematopoietic tumors such as carcinoma, sarcoma, or melanoma which may show histologic similarities.
| |
| − | | |
| − | ==Familial Forms==
| |
| − | | |
| − | *None known
| |
| − | | |
| − | ==Additional Information==
| |
| − | | |
| − | Put your text here
| |
| − | | |
| − | ==Links==
| |
| − | | |
| − | [[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma]]
| |
| − | | |
| − | Put your links here (use "Link" icon at top of page)
| |
| − | | |
| − | ==References==
| |
| − | (use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted.''</span> <span style="color:#0070C0">''If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">) </span> <references />
| |
| − | | |
| − | '''
| |
| − | | |
| − | ==Notes==
| |
| − | <nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.
| |
| − | | |
| − | <nowiki>*</nowiki>The hierarchical tumour classification structure displayed on this page is reproduced from the [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours] with permission from the copyright holder, ©International Agency for Research on Cancer.
| |
| − | | |
| − | <nowiki>*</nowiki>''Citation of this Page'': “Follicular dendritic cell sarcoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Follicular_dendritic_cell_sarcoma</nowiki>.
| |
| − | [[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases F]]
| |